Compared with standard chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. | Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations